Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genkyotex    GKTX   FR0011790542

GENKYOTEX

(GKTX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed Euronext Paris - 02/18 11:06:03 am
0.942 EUR   +1.07%
01/09GENKYOTEX : Liquidity contract balance at December 31, 2018
PU
2018GENKYOTEX SA : half-yearly earnings release
2018GENKYOTEX : Half-yearly report on Genkyotex's liquidity contract
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/12/2019 02/13/2019 02/14/2019 02/15/2019 02/18/2019 Date
0.941(c) 0.933(c) 0.938(c) 0.932(c) 0.942 Last
82 188 52 491 35 461 41 100 29 883 Volume
-1.98% -0.85% +0.54% -0.64% +1.07% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -13,9 M
Net income 2018 -11,5 M
Finance 2018 8,00 M
Yield 2018 -
Sales 2019 50,0 M
EBIT 2019 29,5 M
Net income 2019 52,0 M
Debt 2019 2,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 3,29
EV / Sales2018 0
EV / Sales2019 1,52x
Capitalization 74,0 M
More Financials
Company
Genkyotex specializes in the development of NOX therapies. The group adopts a therapeutic approach based on the selective inhibition of NOX enzymes that boost numbers of pathological processes including fibrosis, inflammation, pain sensation, cancer progression and neurodegeneration. At the end of... 
More about the company
Surperformance© ratings of Genkyotex
Trading Rating : Investor Rating : -
More Ratings
Latest news on GENKYOTEX
01/09GENKYOTEX : Liquidity contract balance at December 31, 2018
PU
2018GENKYOTEX : Announces Presentation of GKT831 Efficacy Data in a Preclinical Mode..
AQ
2018GENKYOTEX : Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 f..
AQ
2018GENKYOTEX SA : half-yearly earnings release
2018GENKYOTEX : Announces Investigator-Initiated Phase 2 Clinical Trial to be Conduc..
AQ
2018GENKYOTEX : Half-yearly report on Genkyotex's liquidity contract
PU
2018GENKYOTEX : Announces Positive Outcome from Independent SMBs First Pre-Planned R..
AQ
2017GENKYOTEX SA : half-yearly earnings release
2017GENKYOTEX : Summary of Genkyotex's liquidity contract with ODDO Corporate Financ..
PU
2017GENTICEL BECOMES “GENKYOTEX&RD : Genticel's General Meeting approves the s..
PU
More news
Analyst Recommendations on GENKYOTEX
More recommendations
Sector news : Bio Therapeutic Drugs
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Bio Therapeutic Drugs
Chart GENKYOTEX
Duration : Period :
Genkyotex Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENKYOTEX
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,10 €
Spread / Average Target 233%
EPS Revisions
Managers
NameTitle
Elias Papatheodorou Chief Executive Officer & Director
Claudio Nessi Chairman
Alexandre Grassin Vice President-Finance & Administration
Philippe Wiesel Chief Medical Officer & Executive Vice President
Jesús Martin-Garcia Director
Sector and Competitors
1st jan.Capitalization (M$)
GENKYOTEX-8.27%84
GILEAD SCIENCES8.06%87 436
VERTEX PHARMACEUTICALS13.49%48 081
REGENERON PHARMACEUTICALS13.51%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252